Your Yourlocation: Home > Efficacy and safety of tiotropium bromide(136310-93-5) and budesonide /formoterol in the treatment of chronic obstructive pulmonary disease

To observe the effect of combined inhalation of tiotropium bromide(136310-93-5) and budesonide / formoterol on chronic obstructive pulmonary disease (COPD), to reduce acute exacerbation of COPD and improve lung function and health status of patients. 

Methods: 86 patients with COPD were divided into three groups according to the random number table method. The combined treatment group (n = 29) received inhaled budesonide / formoterol inhalant 160μg / 4.5μg twice daily and inhaled tiotropium bromide(136310-93-5) (180μg / 4.5μg, 2 times a day); 28 patients in the tiotropium group (18μg, once daily), the course of treatment For 3 months. Results: The pulmonary function, clinical symptoms and health status of the three groups were significantly improved, and the forced expiratory volume was (1.24 ± 0.18) L in the combined treatment group, which was 11.7% higher than that before the experiment. The number of times of relieving drug use and the number of acute attack in the combination therapy group were significantly lower than those in the other two groups (P <0.01), and the difference was statistically significant (P <0.01); combination therapy group St. The score of George Respiratory Disease(SGRQ) was (35.6 ± 13.9), which was significantly lower than that of the other two groups (P <0.01). There was no significant difference in the incidence of adverse events between the three groups (p> 0.05). 

Conclusion: Combined inhalation of tiotropium bromide(136310-93-5) and budesonide /formoterol in the treatment of COPD can control the clinical symptoms of patients and improve lung function, the effect is better than monotherapy, no adverse reactions.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved